共 17 条
Simple clinical risk score for no-reflow prediction in patients undergoing primary Percutaneous Coronary Intervention with acute STEMI
被引:28
作者:
Dogan, Nazile Bilgin
[1
]
Ozpelit, Ebru
[2
]
Akdeniz, Selma
[3
]
Bilgin, Muzaffer
[4
]
Baris, Nezihi
[5
]
机构:
[1] Menemen State Hosp, Dept Cardiol, Izmir, Turkey
[2] DokuzEylul Univ Hosp, Dept Cardiol, Izmir, Turkey
[3] AKUT Cardiovasc Hosp, Dept Cardiol, Izmir, Turkey
[4] Eskisehir Osmangazi Univ, Dept Biostat, Eskisehir, Turkey
[5] DokuzEylul Univ Hosp, Dept Cardiol, Izmir, Turkey
关键词:
No-reflow;
Risk score;
ST-segment elevation myocardial infarction (STEMI);
Percutaneous coronary intervention;
ACUTE MYOCARDIAL-INFARCTION;
INSULIN-GLUCOSE INFUSION;
DIABETES-MELLITUS;
MORTALITY;
HYPERGLYCEMIA;
ASSOCIATION;
ADMISSION;
DIGAMI;
D O I:
10.12669/pjms.313.7484
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objectives: To identify the STEMI patients at high risk in terms of no-reflow during percutaneous coronary intervention (PCI) with a simple risk score system that can be used before reperfusion. Methods: Total 173 patients who had undergone primary or rescue percutaneous coronary intervention following the diagnosis of STEMI, were classified as "no-reflow" developers and "no-reflow" non-developers, during the procedure. The pre-procedural ECGs, laboratory parameters, demographic data, time for the treatment, and the treatment methods were evaluated with univariate analysis. The independent predictors were identified by multivariate logistic regression analysis among the no-reflow risk factors. Using the independent predictors, we developed a simple risk score system proportional to area under the ROC (AUROC) curves. Results: The independent predictors of "no-reflow" phenomenon were identified as follows: high values of blood glucose at reference; long symptom-onset-to-balloon-time; and low lymphocyte count. The incidence rates of "no-reflow" in patients with low (0-1), moderate (2-3) and high (4-6) risk factors were 13.3%, 40.0%, and 46.7%, respectively. The risk score system demonstrated a good risk prediction between patients with various risk levels of the development of "no-reflow" with a c-statistics of 0.734 (95% CI 0.654-0.814). Conclusion: The development of "no-reflow" which is an adverse event in STEMI treatment can be predicted efficiently by simple clinical risk scoring method.
引用
收藏
页码:576 / 581
页数:6
相关论文